- New antiobesity medications such as tirzepatide and semaglutide do not meet standard cost-effectiveness thresholds at their current net prices.
- The study projected substantial reductions in obesity, diabetes, and cardiovascular disease cases with these medications.
- Efforts to reduce the net prices of new antiobesity medications are essential for ensuring equitable access.
- Among the medications studied, only naltrexone-bupropion was found to be cost-saving.
- The study cohort included 4,823 individuals representing 126 million eligible U.S. adults aged 20 to 79 years.
- The researchers emphasized the exacerbation of obesity disparities due to the high net prices of antiobesity medications.
- Policy solutions, including Medicare price negotiations, were suggested to improve affordability and accessibility of obesity treatment.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
